A new genome-wide screening platform has identified specific cellular barriers that limit nonviral gene editing. Researchers published these findings in Nature Communications, detailing how the human body naturally restricts the delivery of gene-editing components to the cell nucleus. This discovery changes how scientists approach therapeutic delivery by shifting the focus from the transport vehicle to the host cell itself.
Nonviral delivery methods often struggle with efficiency compared to viral vectors. By conducting a CRISPR knockout screen across over 19,000 human genes, the research team found 26 specific genes that act as gatekeepers. When these genes are suppressed, the effectiveness of CRISPR-Cas9 and base editors increases significantly. The study highlighted two genes, GJB2 and BET1L, as primary targets for this intervention.
In laboratory tests, suppressing these two specific genes improved editing efficiency by more than six times. The researchers also validated these results using retinal cells from patients with Leber congenital amaurosis, where editing efficiency increased more than three-and-a-half times. This approach allows for transient modulation, meaning the cellular barriers are lowered just long enough to perform the edit before the cell returns to its normal state.
This method offers a path toward more effective genetic medicines for difficult-to-treat tissues. By conditioning the host cell to accept lipid-based nanoparticles more readily, scientists can improve the potency of future treatments. Experts believe this methodology could extend beyond genome editing to improve the delivery of various other medical payloads packaged into similar lipid delivery systems.